STARD5

Across TCGA pan-cancer cohorts, STARD5 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated STARD5 data layer compared with 29 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher STARD5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STARD5 expression acts as an unfavorable survival marker.

HNSC, ESCA, and CHOL are the cancer types where STARD5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.186	0.752	<.001	48	view →
ESCA	OS	Median	II,III,IV	0.130	0.703	<.001	24	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

STARD5–HNSC (OS)

Open the HNSC breakdown →